Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

September 15, 2024

Study Completion Date

June 30, 2025

Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG

Saracatinab

125 mg once daily by mouth for 24 weeks

DRUG

Placebo

once daily by mouth for 24 weeks

Trial Locations (4)

10029

Icahn School of Medicine at Mount Sinai, New York

75246

Baylor University Medical Center (BUMC), Dallas

80206

National Jewish Health, Denver

06510

Yale University School of Medicine, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Yale University

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

AstraZeneca

INDUSTRY

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

collaborator

Baylor University

OTHER

collaborator

International Center for Health Outcomes and Innovation Research

OTHER

lead

National Jewish Health

OTHER